From a clinical perspective, dampening of the initial pro-inflammatory response by KYE28-treatment, especially reducing IL-6, and MCP-1, which have been associated with organ dysfunction, severity of the disease and mortality [50]–[53], may aid in preventing the development of the detrimental “cytokine storm” and its consequences seen in sepsis [51]. This evidence concerns the gene CCL2 and Sepsis.